Blog
China approves Eli Lilly’s Alzheimer’s treatment Kisunla By Investing.com
INDIANAPOLIS – Eli Lilly and Company (NYSE: NYSE:), a pharmaceutical giant with a market capitalization of…
Meir Statman: Your State of Mind Influences Your Investing Success
Editor’s Note: Our Enterprising Investor podcast features intimate conversations with some of the most influential people…
Ofcom publishes Illegal Harms Codes of Practice
Online harms regulator Ofcom has published its first code of practice for tackling illegal harms…
TCAF: Performance, Factor Nuances Welcome A Skeptical View
TCAF: Performance, Factor Nuances Welcome A Skeptical View #TCAF #Performance #Factor #Nuances #Skeptical #View
Driving government efficiency through better software and IT managment
To truly deliver on the government’s mandate for efficiency savings, ITAM must be viewed not as…
Bain Capital says it will launch tender offer for Fuji Soft without Fuji board approval By Reuters
TOKYO (Reuters) – Bain Capital plans to launch a tender offer for Fuji Soft shares even…
IFRS Accounting Standard Will Support Better Investment Decisions
IFRS 18 Presentation and Disclosure in Financial Statements will usher in the most significant change to…
JPMorgan Chase: Well-Positioned For The Point In The Cycle
JPMorgan Chase: Well-Positioned For The Point In The Cycle #JPMorgan #Chase #WellPositioned #Point #Cycle
Crexendo’s chief strategy officer sells shares worth $783,995 By Investing.com
Anand Buch, Chief Strategy Officer of Crexendo , Inc. (NASDAQ:), recently sold 159,999 shares of the…
SMH Is Now Consolidating (Technical Analysis, Upgrade)
SMH Is Now Consolidating (Technical Analysis, Upgrade) #SMH #Consolidating #Technical #Analysis #Upgrade
Implementation Shortfalls Hamstring Factor Strategies
The finance community has invested much effort to identify new factors that may indicate a security’s…
Using AI to build stronger client relationships in 2025
In an era where customer expectations are higher than ever, integrating artificial intelligence (AI) into…
iTeos Therapeutics: A Perhaps Unjustified Decline To End 2024
iTeos Therapeutics: A Perhaps Unjustified Decline To End 2024 #iTeos #Therapeutics #Unjustified #Decline
Hims & Hers CEO Andrew Dudum sells shares worth $6.24 million By Investing.com
SAN FRANCISCO—Andrew Dudum, the Chief Executive Officer of Hims & Hers Health, Inc. (NYSE:HIMS), recently reported…
State Capitalism in Private Markets: Mission Creep
Governments worldwide have a long and storied history of directing capital flows to and within private…
2025-30: Geopolitical influence on cyber and the convergence of threat
The early 2020’s saw multiple threads of the cyber threat landscape evolve. This was mostly…
ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Light & Wonder, Inc. Investors to Inquire About Securities Class Action Investigation
New York, New York–(Newsfile Corp. – December 17, 2024) – WHY: Rosen Law Firm, a global…
Generational Wealth: Does the Apple Fall Far From the Tree?
Will the son of a billionaire perpetuate his inherited wealth? Apparently not, if history is any…
RPM International: A Protective Business At A Price (NYSE:RPM)
This article was written by Follow The Value Investor has a Master of Science with specialization…
UK consults on opt-out model for training AIs on copyrighted content
The U.K. government is consulting on an opt-out copyright regime for AI training that would require…